BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 22215907)

  • 1. Hsp90 molecular chaperone inhibitors: are we there yet?
    Neckers L; Workman P
    Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S; Workman P
    Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90: an emerging target for breast cancer therapy.
    Beliakoff J; Whitesell L
    Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90: a novel target for cancer therapy.
    Solit DB; Rosen N
    Curr Top Med Chem; 2006; 6(11):1205-14. PubMed ID: 16842157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old and New Approaches to Target the Hsp90 Chaperone.
    Sanchez J; Carter TR; Cohen MS; Blagg BSJ
    Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action.
    Matts RL; Manjarrez JR
    Curr Top Med Chem; 2009; 9(15):1462-78. PubMed ID: 19860729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux.
    Samarasinghe B; Wales CT; Taylor FR; Jacobs AT
    Biochem Pharmacol; 2014 Feb; 87(3):445-55. PubMed ID: 24291777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.
    Jhaveri K; Taldone T; Modi S; Chiosis G
    Biochim Biophys Acta; 2012 Mar; 1823(3):742-55. PubMed ID: 22062686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HSP90 molecular chaperones: moving into the clinic.
    Garcia-Carbonero R; Carnero A; Paz-Ares L
    Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
    Xiao L; Lu X; Ruden DM
    Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective.
    Workman P
    Adv Exp Med Biol; 2020; 1243():163-179. PubMed ID: 32297218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.